期刊文献+

吉西他滨白蛋白纳米粒对胰腺癌细胞株体外抑制效应的实验研究 被引量:2

Effect of 406 nm-gemcitabine-loaded albumin nanoparticles on in vitro human pancreatic cancer cells CFPAC-1
下载PDF
导出
摘要 目的:通过体外实验,探讨406nm吉西他滨白蛋白纳米颗粒(406nm-GEM-NP)对人胰腺癌细胞株CFPAC-1体外增殖的抑制效应。方法:以人胰腺癌细胞株CFPAC-1为研究对象,分为4个给药组:406nm-GEM-NP组、单纯GEM组、空白纳米颗粒组和无药对照组,采用MTT法(四甲基偶氮唑蓝)观察不同药物浓度对肿瘤细胞生长的抑制作用;并同时观察给药后48h和72h肿瘤细胞的增殖抑制率。结果:MTT试验检测提示406nm-GEM-NP和GEM均具有显著的细胞抑制作用,且406nm-GEM-NP的细胞抑制率在50μg/mLGEM浓度时,超过了单纯GEM(P<0.05),且有明显的时间依赖性,提示有显著的药物缓释作用;空白纳米颗粒对细胞抑制轻微,且不具有时间和浓度依赖性。结论:406nm-GEM-NP对人胰腺癌细胞株CFPAC-1具有显著的体外细胞增殖抑制作用。 Objective To investigate the anti-proliferation effect of 406 nm-gemcitabine (GEM)-loaded albumin nanoparticles on human pancreatic cancer cells, CFPAC-1, in vitro. Methods CFPAC-1 cells were treated with 406 nm-GEM-loaded albumin nanoparticles, pure GEM, blank albumin nanoparticles and culture fluid respectively. CFPAC-1 cell growth inhibition rates in different groups were detected by M3W essay; and also, the growth inhibition rates were detected at 48 h and 72 h after drug administration. Results The 406 nm-GEM-NP group and GEM group produced significant anti-proliferation effect on CFPAC-1 cell gruwth. The 406 nm-GEM-NP group had higher inhibitory effect than the GEM group using the concentration of 50 μg/mL GEM(P〈0.05), and its inhibitory effect at 72 hours was much higher than that of at 48 hours. Blank albumin nanoparticles produced trifle inhibition on the CFPAC-1 cells without correlation to time or concentration. Conclusions 406 nm-GEM-NP has a significant anti-proliferation effect on the pancreatic cancer cells CFPAC-1 with time-dependence in vitro.
出处 《外科理论与实践》 2009年第6期644-647,共4页 Journal of Surgery Concepts & Practice
基金 上海市经委项目(沪产学研06-23) 上海市科委项目(08431902500)
关键词 吉西他滨 纳米粒 白蛋白 胰腺癌 人胰腺癌细胞株(CFPAC—1) Gemcitabine Nanoparticle Albumin Pancreatic cancer Human pancreatic cancer cell lines ( CFPAC- 1 )
  • 相关文献

参考文献17

  • 1O'Driscoll L, Walsh N, Larkin A. et al. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma[J], Anticancer Res,2007,27(4B):2115-2120.
  • 2Konig J, Hartel M, Nies AT, et al. Expression and locahzation of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma[J]. Int J Cancer, 2005,115(3):359-367.
  • 3Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers [J]. Curr Pharm Des,2008,14(11): 1124-1137.
  • 4Reddy LH, Khoury H, Paci A, et al. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice [J]. Drug Metab Dispos,2008,36(8): 1570-1577.
  • 5Eli Lilly Co. Summary of product characteristies:gemcitabine UK prescribing information[R]. Eli Lilly,1997.
  • 6Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy[J]. Technol Cancer Res Treat,2005,4(4):363- 374.
  • 7李金明,陈卫,龙江,金忱,陆伟跃,倪泉兴,傅德良,侯惠民.吉西他滨白蛋白纳米粒的制备及其对胰腺癌细胞的毒性研究[J].中华胰腺病杂志,2008,8(5):295-297. 被引量:2
  • 8Jin-ming LI,Wei CHEN,Hao WANG,Chen JIN,Xian-jun YU,Wei-yue LU,Long CUI,De-liang FU,Quan-xing NI,Hui-min HOU.Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro[J].Acta Pharmacologica Sinica,2009,30(9):1337-1343. 被引量:5
  • 9傅德良,徐近,龙江,虞先浚,金忱,李骥,狄扬,倪泉兴,张延龄.可切除性胰腺癌多时相介入综合治疗的临床研究[J].外科理论与实践,2006,11(6):492-495. 被引量:5
  • 10Yang J, Park SB, Yoon HG, et al. Preparation of polyepsiloncaprolactone nanoparticles containing magnetite for magnetic drug carrier[J]. Int J Pharm,2006,324(2):185- 190.

二级参考文献17

  • 1陈锋,李春忠.抗癌丝裂霉素白蛋白微球的制备及体外释药性能[J].华东理工大学学报(自然科学版),2006,32(2):184-187. 被引量:8
  • 2Yamaue H,Tani M,Onishi H,et al.Locoregional chemotherapy for patients with pancreatic cancer intraarterial adjuvant chemotherapy after pancreatectomy with portal vein resection[J].Pancreas,2002,25(4):366-372.
  • 3Cantore M,Pederzdi P,Cornalba G,et al.Intra-arterial chemotherapy for unresectable pancreatic cancer[J].Ann Oncol,2000,11(5):569-573.
  • 4Beger HG,Gansauge F,Buchler MW,et al.Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer:significant reduction in occurrence of liver metastasis[J].World J Surg,1999,23(9):946-949.
  • 5Papachristou E,Link KH,Schoenberg MH.Regional celiac artery infusion in the adjuvant treatment of pancreatic cancer[J].Anticancer Res,2003,23(2A):831-834.
  • 6LANGER K,BALTHASAR S,VOGEL V,et al.Optimization of the preparation process for human serum albumin (HSA) nanoparticles[J].Int J Pharm,2003,257 (1-2):169-180.
  • 7EDWARDS-LEVY F,ANDRY M C,LEVY M C.Determination of free amino group content of serum albumin microcapsules using trinitrobenzensulfonic acid:effect of variations in polycondensation pH[J].Int J Pharm,1993,96(1-3):85-90.
  • 8BRIGGER I,DUBEMET C,COUVREUR P.Nanoparticles in cancer therapy and-diagnosis[J].Adv Drug Deliv Rev,2002,54(5):631-651.
  • 9WARTLICK H,SCHMITT B S,STREBHARDT K,et al.Tumor cell delivery of antisense oligonucleotides by human serum albumin nanoparticles[J].J Controlled Release,2004,96 (3):483-495.
  • 10Xiang-xi MENG,Jia-qi WAN,Meng JING,Shi-guang ZHAO,Wei CAI,En-zhong LIU.Specific targeting of gliomas with multifunctional superparamagnetic iron oxide nanoparticle optical and magnetic resonance imaging contrast agents[J].Acta Pharmacologica Sinica,2007,28(12):2019-2026. 被引量:6

共引文献22

同被引文献10

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部